- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Eli Lilly and Co.
Roche acquires Marcadia Biotech
December 30, 2010
Chris O'MalleyMarcadia Biotech Inc., a Carmel-based biopharmaceutical company founded by prominent scientists from Eli Lilly and Co. in
2006, has been acquired by Swiss life sciences giant Roche.
MoreEli Lilly puts faith in drug pipeline
December 24, 2010
J.K. WallEli Lilly and Co. started to tip over its massive “patent cliff” this year, yet announced little publicly that
will significantly soften its inevitable sales plunge.
MoreLilly suspends late-stage trial for melanoma drug
December 13, 2010
Bloomberg NewsEli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study
died.
MoreContrarians think it's new day for Lilly
December 1, 2010
J.K. WallThe trouble-free market approval obtained by Eli Lilly and Co. for a new underarm testosterone treatment brightened the company’s
outlook—at least for one of the few optimistic analysts covering the company.
MoreLilly, Acrux receive FDA approval for Axiron
November 24, 2010
IBJ Staff and Bloomberg NewsThe companies believe the underarm testosterone solution has the potential to realize sales of more than $1 billion a year
in the United States.
MoreLilly scores series of small victories
November 17, 2010
J.K. WallThe Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended
off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
MoreCourt upholds Lilly patent on cancer drug Alimta
November 16, 2010
IBJ Staff and Associated PressA U.S. District Court judge on Monday upheld Eli Lilly and Co.’s patent on the cancer drug Alimta, protecting the compound
until July 2016. It was a welcome win after a difficult few months for Indianapolis-based Lilly, which is facing a wave of
patent expirations in coming years.
MoreRolls-Royce eyeing former Lilly campus downtown
November 15, 2010
If the manufacturer and drugmaker can come to an agreement, Rolls-Royce would lease the space formerly occupied by Eli Lilly
and Co. and relocate some of its 2,500 employees to the downtown campus on South Meridian Street. Discussions are expected
to last several months.
MoreDrugmakers seek Republican allies to defeat cost-cutting panel
November 15, 2010
Bloomberg NewsPharmaceutical firms led by Eli Lilly are trying to eliminate a government panel aimed at controlling Medicare spending seven
months after they supported the health-care overhaul that created it.
MoreStudy: Arthritis drug co-developed by Lilly shows promise
November 12, 2010
IBJ Staff and Bloomberg NewsLilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications
for autoimmune diseases.
MoreAcquisition big step for Lilly Diagnostics
November 10, 2010
J.K. WallEli Lilly and Co.’s $800 million acquisition of Avid Radiopharmaceuticals Inc. is the biggest step yet in the drugmaker’s
attempt to add diagnostics to its product portfolio.
MoreDrugmaker restarts race to boost 'good' cholesterol
November 10, 2010
Bloomberg NewsMerck & Co. is betting it can succeed where Pfizer Inc. failed, with a new type of drug to combat heart disease by raising
good cholesterol levels. Indianapolis-based Eli Lilly and Co. is testing a similar pill.
MoreMoody's downgrades long-term ratings for Eli Lilly
November 9, 2010
Associated PressMoody's Investors Service on Monday lowered the long-term ratings of Lilly one notch, to A2 from A1, citing a wave of patent
expirations the drugmaker faces in coming years.
MoreLilly makes $300M deal for Philadelphia drug company
November 8, 2010
J.K. WallEli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients
with Alzheimer's disease. The price could climb to $800 million if the agent is commercially successful.
MoreLilly wins approval of antidepressant Cymbalta for pain
November 4, 2010
Bloomberg NewsThe Food and Drug Administration has cleared Cymbalta for musculoskeletal pain such as arthritis and chronic lower back conditions,
which could mean another $500 million in annual sales for Lilly, an analyst estimates.
MoreGroup says billboard companies rejected anti-Lilly ad
November 3, 2010
Scott OlsonSan Francisco-based Breast Cancer Action wanted its message, "Eli Lilly is making us sick. Tell them to stop," posted on local
billboards. But numerous sign companies refused, the group said.
MoreSeeking growth, Lilly dumps Singapore for China
November 3, 2010
J.K. WallAfter recently deciding to close a research center in Singapore, Indianapolis-based Eli Lilly and Co. has decided to open
a diabetes research center in China in the second half of 2011, further ramping up the drugmaker's presence in the world's
fastest-growing pharmaceutical market.
MoreLilly to open diabetes research center in China
November 2, 2010
IBJ StaffIndianapolis-based Eli Lilly and Co. plans to open a diabetes research center in China, the drugmaker said Tuesday, citing
the high incidence of the disease there.
MoreAppeals court rejects Lilly over Gemzar patent
November 1, 2010
IBJ Staff and Bloomberg NewsWithout an appeal, generic drugs are now poised to wipe away most of Lilly's $750 million in annual U.S. revenue from Gemzar.
MoreIndiana's life sciences industry sees trouble ahead
October 30, 2010
Associated PressIndiana's life sciences industry has weathered the recession relatively well, but Eli Lilly's struggles and tight capital
markets could threaten the future.
MoreBioCrossroads helping laid-off life sciences workers land safely
October 30, 2010
Chris O'MalleyIndiana firms have dismissed more than 1,400 life science workers over the last two years. Now BioCrossroads has launched
a website that aims to keep that talent in the state.
MoreEli Lilly will have to beat odds to meet drug-rollout goals
October 30, 2010
J.K. WallEli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per
year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs
in back-to-back years.
MoreIndianapolis-area experts see bright spots amid ongoing real estate weakness
October 23, 2010
Health care shows signs of life, and multi-family buildings continue to hold their own, experts said during a recent IBJ
Power Breakfast.
MoreAnalysts: Lilly setbacks might spur shopping spree
October 22, 2010
Bloomberg NewsCEO John Lechleiter claims Eli Lilly and Co. isn't interested in big acquisitions to bolster its flagging drug pipeline, but
its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
MoreAnalysts grill Lilly execs on strategy after setbacks
October 21, 2010
J.K. WallWall Street analysts on Thursday demanded to know what new things Eli Lilly and Co. is planning since the company’s vaunted
pipeline has failed to produce a drug that will boost revenue after a wave of patent expirations. The answer: Not much.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
First, the Athenaeum is going to have to get past the hurdle with the Lockerbie residents and the agreement that the parcel would be residential. Second, and in my opinion, this prime piece of property should include parking, PLUS, a black box theater(s), some market rate and affordable artist housing and a plan to renovate and reconfigure the second story theater. I would negotiate to add the DeHaan property surface parking lot into the development mix, place a one story surface parking garage on the DeHaan lot on the street level (for the Dehaan tenants use during the daytime) and add a second story to the garage that would become an addition to the current second story theater and then change the direction of the theater by moving the stage across the alley and on top of the DeHaan lot parking. You can add all the stage elements that are currently missing from the Athenaeum stage to make it more attractive for use by Ballet, Opera and traveling productions. Plus, the theater changes would probably help solve some of the soundproofing issues. Alas,it does not seem to be a part of the strategic plan to conduct a study to determine best use of the property. Seems like the current plan is a quick and easy move that ignores the property best use/potential and any strategic property planning for the effect on future generations.
I recall that MSA's pilings are still in the ground and hard to remove. It’s not likely any proposal will include significant underground construction/parking because of this. Start adding 2 floors of retail, 8 floors of parking and 5-10 floors of possible hotel, and/or 10-20 floors of residential, and you are at 30 floors already with possible expansion of all the uses. But then again I could be wrong.
Accoriding to their website there is no deadline to the Do Not Call list. What is this article referring to??
On what planet are they entitled to this largesse from the stockholders? These people make multi-million dollar salaries: Pay for your own personal travel.
It matters because they're already paid enormously fat salaries: Pay for your own personal travel. Being "taxed on it" isn't a valid excuse--so what? They're still being gifted a raft of luxury perks from somebody else's money on top of an enormous, lavish salary.